J Triebelhorn, J Schneider, C D Spinner, R Iakoubov, F Voit, L Wagner, J Erber, K Rothe, A Berthele, V Pernpeintner, E-M Strauß, L Renders, A Willmann, M Minic, E Vogel, C Christa, D Hoffmann, U Protzer, S D Jeske
PURPOSE: This study assessed the clinical and immunological outcomes of SARS-CoV-2-infected patients with risk factors for severe disease depending on their immunological status. METHODS: In this retrospective study with single follow-up visit, clinical outcome and humoral immunity was monitored in SARS-CoV-2 infected patients at risk. The results were compared based on the patients' initial immunological status: unvaccinated (UV), patients who did not develop neutralizing antibodies after vaccination (vaccine non-responders, VNR), and patients who expressed neutralizing antibodies after vaccination (vaccine responders, VR)...
February 2, 2024: Infection